Miyata A, Deguchi S, Fujita M, Kikuchi T, Honda K
Department of Internal Medicine, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama City, Japan.
Rinsho Ketsueki. 1996 May;37(5):448-51.
A 60-year-old male with hepatocellular carcinoma was treated by repeated intra-arterial injection of epirubicin, carboplatin and doxorubicin. Subsequently, radiotherapy and intravenous administration of etoposide were also carried out. Thirty-three months later he developed AML (M2). The chromosome analysis revealed 45, X, -Y, t (8;21) (q22;q22), which suggested that this leukemia was induced by topoisomerase II targeting agents. He was treated with low dose BHAC and G-CSF and achieved complete remission. This leukemia may be caused by synergic effect of topoisomerase II inhibitors and carboplatin together with radiotherapy. This may be the first report of therapy-related leukemia following chemotherapy for hepatocellular carcinoma.
一名60岁的肝细胞癌男性患者接受了表柔比星、卡铂和阿霉素的反复动脉内注射治疗。随后，还进行了放疗和依托泊苷静脉给药。33个月后，他发展为急性髓系白血病（M2）。染色体分析显示为45,X,-Y,t(8;21)(q22;q22)，这表明这种白血病是由靶向拓扑异构酶II的药物诱导的。他接受了低剂量的BHAC和粒细胞集落刺激因子治疗并实现了完全缓解。这种白血病可能是由拓扑异构酶II抑制剂与卡铂以及放疗的协同作用引起的。这可能是肝细胞癌化疗后治疗相关白血病的首例报告。
